# Enzymax DuoBiotics for Irritable Bowel Syndrome

> **NCT07716852** · NA · NOT_YET_RECRUITING · sponsor: **Gala Servicios Clinicos S.L.** · enrollment: 120 (estimated)

## Conditions studied

- Irritable Bowel Syndrome
- Irritable Bowel Syndrome (IBS)

## Interventions

- **DIETARY_SUPPLEMENT:** Enzymax DuoBiotics
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT07716852
- **Lead sponsor:** Gala Servicios Clinicos S.L.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2027-06-23
- **Final completion:** 2027-09-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07716852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07716852, "Enzymax DuoBiotics for Irritable Bowel Syndrome". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07716852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*